Centre Hospitalier de Jolimont-Lobbes

La Louviere (Haine-Saint-Paul) 7100

0 studies enrolling now · 2 studies all time

What they study most

Cardiovascular Disease, Follicular Lymphoma

Studies at this site

• A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early